Endocrine Abstracts

Introduction: Before launching of SGL¬T-2 inhibitor, triple combination of TZD with metformin and DPP¬4 inhibitor was best option for delaying progression of diabetes by improving insulin resistance and secretory dysfunction. SGLT-2 inhibitor can be used as first combination therapy with metformin, but add on to any diabetic combination will be favorable in terms of body weight and cardiovascular risk reduction, especially in long duration of diabetes with relatively...